AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21318563
Drug: Nicotine Cannon
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Cannon (NC) and mini-lozenge
Trial: 19703383
Drug: Psycho-educational, coping-oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational, coping-oriented therapy programme (PKB)
Trial: 17867915
Drug: Enoxaparin (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (novel dosing for elderly patients)
Trial: 11701711
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment for 6 days
Trial: 11701711
Drug: IGF-I treatment
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I treatment for 6 days
Trial: 11701711
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment in GHD patients
Trial: 11701711
Drug: Octreotide or
RxNorm normalized name: octreotide Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide or pegvisomant treatment in acromegalic patients for 3 months
Trial: 9219043
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg once a day) plus Pindolol (2.5 mg three times a day)
Trial: 9219043
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg once a day) plus Placebo
Trial: 8279647
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) 6 mg/kg one time or 1 mg/kg, then 6 mg/kg four days later
Trial: 8279647
Drug: Single-dose DEC
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose DEC
Trial: 29779816
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (6 capsules daily, each containing 180 mg EPA and 120 mg DHA)
Trial: 29779816
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 capsules daily)
Trial: 22362836
Drug: Videoconferencing (VC)
RxNorm normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconferencing (VC) administration of RUDAS
Trial: 22362836
Drug: Face-to-face (FTF)
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face (FTF) administration of RUDAS
Trial: 7758177
Drug: TPA 100
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA 100 mg i.v. over 3 hours
Trial: 43966
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg, oral application)
Trial: 43966
Drug: Carazolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carazolol (5 mg)
Trial: 23511704
Drug: Isoflavones (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (100-200 mg daily)
Trial: 23511704
Drug: Twice-daily to
RxNorm normalized name: ClindaMax 1 % Twice-Daily Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily to thrice-daily dosing frequency of isoflavones
Trial: 9865671
Drug: Omacor (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor (4 g/day for 4 months)
Trial: 3219226
Drug: Immunohistochemical assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical assay for estrogen receptor (ER) status in primary tumors and metastases
Trial: 24918629
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume with PEEP (6 mL/kg tidal volume, 5 cm H2O PEEP)
Trial: 24918629
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (10 mL/kg tidal volume, 0 cm H2O PEEP)
Trial: 22569835
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day added to interferon beta‐1b
Trial: 22569835
Drug: Interferon beta‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1b monotherapy
Trial: 11192305
Drug: Heparin pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin pretreatment (HP)
Trial: 11192305
Drug: Non-heparin pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin pretreatment (NHP)
Trial: 25611962
Drug: Tadalafil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (1 mg/kg daily)
Trial: 25611962
Drug: Tadalafil administration
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil administration
Trial: 25649903
Drug: Laparoscopy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopy with fast-track treatment (LAFT)
Trial: 25649903
Drug: Open surgery
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgery with fast-track treatment (OSFT)
Trial: 25649903
Drug: Laparoscopy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopy with conventional treatment (LAC)
Trial: 25649903
Drug: Open surgery
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgery with conventional treatment (OSC)
Trial: 12880608
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (400 ml daily of a supplement enriched with protein, arginine, zinc and antioxidants)
Trial: 12880608
Drug: Placebo (non-caloric,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (non-caloric, water-based supplement)
Trial: 11082935
Drug: Anthocyanins administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins administered to 50 women
Trial: 11082935
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to 55 women
Trial: 9361661
Drug: Telephone Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone Cognitive Assessment Battery (TCAB) administered before in-person assessment
Trial: 1489122
Drug: Atropine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.5 mg intranasally)
Trial: 20354453
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m on days 1 and 8 (G)
Trial: 20354453
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m on days 1 and 8 plus docetaxel 75 mg/m on day 1 (GD)
Trial: 12633794
Drug: PMLR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMLR with optimal medical therapy (n = 36)
Trial: 12633794
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone (n = 37)
Trial: 10852758
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) plus albuterol
Trial: 10852758
Drug: Albuterol plus
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol plus placebo (control)
Trial: 8261405
Drug: Oral VP16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral VP16 daily for up to 21 days (Arm A)
Trial: 8261405
Drug: Oral VP16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral VP16 daily for up to 21 days plus concomitant GM-CSF at 5 micrograms/kg/day (Arm B)
Trial: 8261405
Drug: Oral VP16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral VP16 daily for up to 21 days plus pretreatment with GM-CSF (Arm C)
Trial: 3913184
Drug: Adequate medical
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate medical treatment
Trial: 30635781
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimen comprising mainly of anthracyclines and cytarabine (arm A)
Trial: 21329971
Drug: Vero-cell-culture-derived influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero-cell-culture-derived influenza vaccine
Trial: 17192500
Drug: 15-mg pioglitazone/500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg pioglitazone/500-mg metformin fixed-dose combination tablets
Trial: 17192500
Drug: 15-mg pioglitazone/500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg pioglitazone/500-mg metformin coadministration of commercial tablets
Trial: 17192500
Drug: 15-mg pioglitazone/850-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg pioglitazone/850-mg metformin fixed-dose combination tablets
Trial: 17192500
Drug: 15-mg pioglitazone/850-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg pioglitazone/850-mg metformin coadministration of commercial tablets
Trial: 15358467
Drug: Mifepristone 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 75 mg in capsule form followed by misoprostol 600 microg
Trial: 15358467
Drug: Mifepristone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 150 mg in tablet form followed by misoprostol 600 microg
Trial: 1417013
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg intravenous injection)
Trial: 1417013
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (4 mg intravenous dose of ondansetron)
Trial: 26159792
Drug: Uric Acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric Acid (UA) 1000 mg
Trial: 18188581
Drug: Creatine (CR)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (CR) supplementation (approximately 10 g day(-1) over 3 months)
Trial: 12719441
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 to 4 mg, n=28)
Trial: 12719441
Drug: Telmisartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (80 to 160 mg, n=29)
Trial: 12719441
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30 to 60 mg, n=28)
Trial: 12719441
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 to 10 mg, n=28)
Trial: 12719441
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg, n=29)
Trial: 12719441
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 to 10 mg, n=28)
Trial: 10818412
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CA) COC (2 mg CA + 0.035 mg ethinylestradiol)
Trial: 10818412
Drug: Desogestrel (D)
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desogestrel (D) COC (0.150 mg D + 0.030 mg ethinylestradiol)
Trial: 8804868
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg each morning and clarithromycin 500 mg three times daily for 2 weeks
Trial: 8804868
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg twice daily and clarithromycin 500 mg three times daily for 2 weeks
Trial: 1611221
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation of 800 mg daily (as calcium lactate gluconate)
Trial: 1611221
Drug: Load-bearing exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Load-bearing exercise four times a week plus a daily placebo tablet
Trial: 1611221
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation daily and load-bearing exercise four times a week
Trial: 1611221
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily
Trial: 27555316
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for 5 days
Trial: 26069138
Drug: Right lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right lateral position (group L)
Trial: 17486348
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose steroid treatment for optic nerve neuritis
Trial: 17486348
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment for traumatic optic neuropathy
Trial: 16294137
Drug: Daily alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily alendronate therapy
Trial: 31318038
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine at a dose of 2 mcg/kg (max 100 mcg)
Trial: 31318038
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam at a dose of 0.5 mg/kg (max 15 mg)
Trial: 21920001
Drug: Ramosetron 5μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 5μg once daily
Trial: 19369404
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) - target dosage 3 g/d
Trial: 19369404
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (IVC) - 0.5 to 1.0 g/m(2) in monthly pulses
Trial: 19369404
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d
Trial: 15522039
Drug: Iontophoretic administration
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoretic administration of acetylcholine (ACh)
Trial: 8324641
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 3526151
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg every six hours)
Trial: 29185022
Drug: Quetiapine ER
RxNorm normalized name: quetiapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine ER (daily dose range 50 to 800 mg)
Trial: 29185022
Drug: Aripiprazole (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (daily dose range 2.5 to 30 mg)
Trial: 20829157
Drug: Cold lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold lateral compaction with 0.02 taper gutta‐percha cones and AH 26 sealer cement
Trial: 20829157
Drug: Cold lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold lateral compaction with 0.02 taper Resilon cones and Epiphany sealer
Trial: 20829157
Drug: Single cone
RxNorm normalized name: Pinus strobus cone extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cone technique with 0.04 taper Resilon cones and Epiphany sealer
Trial: 19055278
Drug: Acupuncture-medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-medicine group (scalp electroacupuncture + Nimodipine)
Trial: 19055278
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Nimodipine only)
Trial: 19055278
Drug: Acupuncture-medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-medicine group and Electroacupuncture group
Trial: 7583550
Drug: Major locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major locus with a codominant mixture model including sex, age, plasma concentrations of apoAI and triglycerides, exogenous sex hormone use, and menopausal status.
Trial: 2285001
Drug: Naftidrofuryl (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (oral formulation)
Trial: 29955161
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (48IU/day, n=53)
Trial: 10572081
Drug: PEG‐rHuMGDF (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rHuMGDF (2.5 microg/kg/d or 5 microg/kg/d for up to 21 doses)
Trial: 10572081
Drug: PEG‐rHuMGDF (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rHuMGDF (2.5 microg/kg, single dose) and 7 daily doses of 2.5 microg/kg
Trial: 26959810
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment group
Trial: 26959810
Drug: Non-treatment mTBI
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment mTBI group
Trial: 18560642
Drug: Amalgam plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amalgam plus dentin adhesive plus composite resin with modified preparation design (ADACM)
Trial: 20031608
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR treatment
Trial: 17257175
Drug: dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone 4 mg i.v.
Trial: 17257175
Drug: betamethasone 12
RxNorm normalized name: Betamethasone 120 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: betamethasone 12 mg i.m.
Trial: 18080351
Drug: 0.5% PRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% PRO 2000 or matched placebo gel
Trial: 9382514
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of 5-FU, epirubicin and MMC (FEM group: n=7)
Trial: 9382514
Drug: Other antineoplastic
RxNorm normalized name: OTHER ANTINEOPLASTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antineoplastic agents (non-FEM group: n=10)
Trial: 2875907
Drug: Temelastine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temelastine 50 mg
Trial: 2875907
Drug: Temelastine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temelastine 100 mg
Trial: 2875907
Drug: Temelastine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temelastine 200 mg
Trial: 2875907
Drug: Chlorpheniramine 4
RxNorm normalized name: chlorpheniramine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 4 mg (Control)
Trial: 24072969
Drug: Self-administered training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered training
Trial: 19263014
Drug: OMM: omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMM: omeprazole 20 mg twice a day, moxifloxacin 400 mg/day, metronidazole 500 mg three times a day
Trial: 19263014
Drug: OBMT: omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBMT: omeprazole 20 mg twice a day, colloidal bismuth subcitrate 120 mg four times a day, metronidazole 500 mg three times a day, tetracycline 500 mg four times a day
Trial: 8304833
Drug: rPDGF‐BB 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPDGF‐BB 100 micrograms/mL
Trial: 8304833
Drug: rPDGF‐BB 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPDGF‐BB 300 micrograms/mL
Trial: 16991062
Drug: Bilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sequential total knee arthroplasty under one anaesthesia session
Trial: 15152279
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 microg three times daily subcutaneously)
Trial: 9274455
Drug: i.v. 5-dFUR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. 5-dFUR 3000 mg/m2 with L-leucovorin 25 mg/dose on days 1-5, every 3 weeks
Trial: 9274455
Drug: oral 5-dFUR
RxNorm normalized name: 5'-DFUR
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 5-dFUR 1200 mg/m2 for 5 days followed by 5 days off with oral L-leucovorin 25 mg/dose 2 h before 5-dFUR
Trial: 9274455
Drug: oral 5-dFUR
RxNorm normalized name: 5'-DFUR
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 5-dFUR
Trial: 3729450
Drug: Estradiol administration
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol administration every 7 days
Trial: 3729450
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of OK-432 or LENTINAN
Trial: 24278177
Drug: Formalin-inactivated EV71
RxNorm normalized name: formalin
DrugBank: Formaldehyde (DB03843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-µg doses
Trial: 21068104
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of the last disease-modifying antirheumatic drug (DMARD) after achieving DAS < 1.6 for ≥ 6 months.
Trial: 21068104
Drug: Restarting treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restarting treatment with DMARD after DAS increased to ≥ 1.6.